NBIX:NASDAQ
Neurocrine Biosciences, Inc
142,44Â USD
arrow_upward
+0,84%(+1,19) 1Â D
142,44Â USD
0,00% (0,00)
bedtimeEtter stengetid
Stengt: 9. okt., 16:00:00 GMT-4 · USD
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for NBIX …
Ã…pne
141,33Â USD
Høy
143,55Â USD
Lav
140,02Â USD
Markedsverdi
14,48Â mrd.
Snittvolum
1,28Â mill.
Volum
1,02Â mill.
P/E-forhold
20,88
52 u høy
186,12Â USD
52Â u lav
122,14Â USD
EPS
6,82Â USD
Beta
0,40
Utestående aksjer
101,65Â mill.
Antall ansatte
2k
Ã…pne
141,33Â USD
Høy
143,55Â USD
Lav
140,02Â USD
Markedsverdi
14,48Â mrd.
Snittvolum
1,28Â mill.
Volum
1,02Â mill.
P/E-forhold
20,88
52 u høy
186,12Â USD
52Â u lav
122,14Â USD
EPS
6,82Â USD
Beta
0,40
Utestående aksjer
101,65Â mill.
Antall ansatte
2k
Nyhetssaker
Fra nettkilder og nyhetspartnere
Zacks
·
for 1 døgn siden
4 CNS Drug Stocks Worth Watching This World Mental Health Day
Simply Wall Street
·
for 2 døgn siden
How Investors Are Reacting To Neurocrine Biosciences (NBIX) New VYKAT XR Data
Profil
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
Om Neurocrine Biosciences, Inc
Administrerende direktørKevin C. Gorman
Ansatte2,5k
Grunnlagt1992
HovedkontorSan Diego, California, USA
Sektor-
Nettstedneurocrine.com